Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $4.27
Volume
1.12 K
Value Traded
104.43 K
Short % Float
0.03%
-1.88%Week
-13.26%1 Month
-43.63%3 Month
-40.3%6 Month
-85.65%5 Year
-85.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
556.86 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
1.06 B
Total Shares
355.76 M
Float Shares
336.82 M
Insiders
5.17%
Institutions
0.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EVO Catalyst Timeline
Dated clinical, regulatory and corporate events for Evotec SE
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evotec SE
19Total events
2Upcoming
5Tier-1 (high impact)
2022 to 2026Coverage
Upcoming catalysts 2
TBD
T3Preclinical PoC
Subscribe to view catalyst details
TBD
T2Management Change
Subscribe to view catalyst details
Event history 14
▲Trial InitiationJST-018Trial
Phase 1 trial of JST-018 initiated in orthopoxvirus program
orthopoxvirus infectionssource ↗
▲Partnership / LicenseCorporate
Evotec and Plectonic enter research collaboration to explore BiTco and LOGIBODY combination for solid tumors
solid tumorssource ↗
▲Product LaunchJ.TRAINPost-Market
Launch of J.TRAIN turnkey continuous manufacturing offering
▲Partnership / LicenseCorporate
U.S. Department of War orthopoxvirus contract awarded to Just – Evotec Biologics
orthopoxvirus infectionssource ↗
▲Grant / FundingCorporate
Orthopoxvirus antibody contract awarded to Just – Evotec Biologics by U.S. Department of War
orthopoxvirus infections (including smallpox and mpox)source ↗
▲Partnership / LicenseCorporate
Initial 2022 Accelerated Antibodies Program award for monoclonal antibodies against plague
plaguesource ↗
▲Grant / FundingCorporate
Initial 2022 program award for monoclonal antibodies against plague
plaguesource ↗
Past FDA Catalysts and PDUFA Decisions
How EVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$16M
Pipeline Value
Not rated
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 90%
Micro Cap(rank 592 of 658)
Percentile Rank
Evotec SE faces pipeline headwinds (22/100), with $69M risk-adjusted pipeline value, led by JST-010 in Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| JST-010 Monoclonal antibodyNCT06943378 | Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults | Phase 1 | ACTIVE NOT_RECRUITING | 104 | Oct 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every EVO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in EVO for Q2 2026. | ||||
EVO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVO ranks across every disease it competes in
Competitive Position is a premium feature
See how EVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVO News
EVOEvotec Announces Chief Scientific Officer Transition
Evotec SE announced that Dr. Cord Dohrmann will step down as Chief Scientific Officer on September 30, 2026. This decision was made by mutual consent, and the search for his successor is underway. Dr. Dohrmann has been with Evotec for 16 years and has played a crucial role in advancing the company's scientific capabilities and innovation culture.
Read more →EVOJust - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Evotec SE has initiated a Phase 1 clinical trial for JST-018, a cocktail of monoclonal antibodies targeting orthopoxviruses. This development is part of the U.S. Department of War's Accelerated Antibodies Program, aimed at creating countermeasures against biological threats like smallpox. The trial marks a significant step in biodefense preparedness, leveraging advanced manufacturing processes.
Read more →EVO▲ +5.6%on this news
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Evotec SE and Plectonic Biotech have announced a collaboration to develop a new immunotherapy approach for solid tumors. This partnership will combine Evotec's BiTco platform, which enhances T cell activation, with Plectonic's LOGIBODY® technology, designed for precise tumor recognition. The goal is to create more effective T cell-engaging therapies for solid tumors, which are notoriously difficult to treat.
Read more →EVOSamenvatting: Evotec selecteert Navan om het globale beheer van reizen, betalingen en uitgaven een te maken
Evotec has chosen Navan to manage its global travel and expense program. This partnership aims to streamline operations in key markets using Navan's AI-driven platform. The collaboration is expected to enhance efficiency and support Evotec's mission in drug discovery and development.
Read more →EVORiassunto: Evotec sceglie Navan per unificare a livello globale viaggi, pagamenti e gestione delle spese
Evotec has selected Navan to manage its global travel and expense program. This partnership aims to improve operational efficiency across Evotec's major markets. Navan's AI-driven platform is expected to provide a comprehensive solution for managing business travel and expenses.
Read more →EVOResumen: Evotec elige a Navan para unificar la gestión mundial de los pagos y viáticos
Evotec has selected Navan to manage its corporate travel and expense program across key global markets. This decision is aimed at streamlining operations and leveraging Navan's AI-driven platform to enhance efficiency. The collaboration marks a significant step for Evotec in optimizing its business processes.
Read more →EVOEvotec choisit Navan pour unifier la gestion mondiale des voyages, des paiements et des notes de frais
Evotec has selected Navan to manage its global travel and expense program across key markets. This partnership will leverage Navan's AI-driven platform to enhance efficiency in travel management. The collaboration is expected to unify Evotec's travel operations and improve overall expense management.
Read more →EVOEvotec entscheidet sich für Navan zur Vereinheitlichung des Managements von Reisespesen und Ausgaben
Evotec has selected Navan to manage its travel and expense management across key global markets. This partnership aims to leverage Navan's AI-supported platform to streamline processes, enhancing operational efficiency for Evotec. The collaboration signifies a strategic move towards modernizing expense management in the life sciences sector.
Read more →EVOEvotec Selects Navan to Unify Global Travel, Payments, and Expense Management
Evotec has chosen Navan to oversee its corporate travel and expense management across key global markets. This collaboration aims to enhance operational efficiency by leveraging Navan's AI-driven platform. The decision reflects Evotec's commitment to modernizing its processes in the life sciences sector.
Read more →EVOAd hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Evotec SE has released preliminary financial results for the second quarter and first half of 2026, indicating a significant drop in expected revenues and EBITDA. The company now anticipates full-year revenues between €570 million and €610 million, down from previous estimates. Adjusted EBITDA is also expected to be negative, reflecting challenges in the current financial landscape.
Read more →EVOJust - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Evotec SE has launched J.TRAIN, a new continuous manufacturing platform for biopharmaceutical companies. This technology enables partners to deploy advanced manufacturing capabilities directly in their facilities, enhancing productivity and reducing costs. With modular cleanroom designs and rapid implementation timelines, J.TRAIN represents a significant advancement over traditional manufacturing methods.
Read more →EVOJust – Evotec Biologics Launches J.TRAIN to Deliver Turnkey ...
Evotec SE has expanded its Just – Evotec Biologics services by launching J.TRAIN, a new offering that allows biopharmaceutical companies to implement Evotec's continuous manufacturing technology in their facilities. This service combines modular cleanrooms and standard manufacturing equipment with cGMP-compliant process automation, promising quicker and more economical deployment compared to traditional methods.
Read more →EVODirectors' Dealings | 16 June 2026 17:46 Notification and public disclosure of transactions by persons discharging manageri responsibilities and persons closely associated with them 16.06.2026 / 17:45 CET/CEST The issuer
On June 15, 2026, Cord Dohrmann, a member of the managing body at Evotec SE, disposed of shares amounting to 576,720 EUR at a price of 4.81 EUR per share. The transaction raises potential concerns among investors regarding management's confidence in the company's future prospects. The trade was conducted on the Xetra trading platform and has been disclosed following regulatory requirements.
Read more →EVOEvotec Reports Results of the Annual General Meeting 2026
Evotec SE held its Annual General Meeting where all agenda items were approved by shareholders. Dieter Weinand and Dr. Wolfgang Hofmann were newly elected to the Supervisory Board, with Weinand appointed as Chairman. Additionally, Dr. Duncan McHale and Wesley Wheeler were re-elected. A total of 43.10% of registered share capital was represented at the meeting.
Read more →EVOEvotec Appoints Rui Wang as Head of Global In Silico and AI
Evotec SE has appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI. With over 20 years of experience, Wang will lead the integration of AI and computational science into Evotec's R&D operations. CEO Christian Wojczewski emphasized the importance of advanced computational tools in enhancing operational efficiency and innovation within the company.
Read more →EVOEvotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec has announced the nomination of a small molecule preclinical development candidate in collaboration with Almirall, aimed at treating immune-mediated inflammatory skin diseases. The program has progressed significantly faster than industry standards, showcasing Evotec's integrated AI/ML-driven R&D capabilities. The partnership aims to address high unmet medical needs in dermatology and will continue towards IND submission.
Read more →EVOFINANCIAL PERFORMANCE REFLECTS CONTINUED SOFTNESS IN D&PD AND LOWER REVENUES IN JUST - EVOTEC BIOLOGICS SEGMENT NEWS FLOW SHOWS STRONG PROGRESS ACROSS STRATEGIC PARTNERSHIPS
Evotec SE faced a challenging financial performance in the first quarter of 2026, with a 21.7% decrease in group revenue compared to the same period in 2025. The Discovery & Preclinical Development (D&PD) segment particularly struggled, reporting a 14.7% decline in revenues. Despite the financial downturn, the company demonstrated progress in strategic partnerships and advancements in organizational transformation. Reorganization costs related to the Project Horizon initiative significantly impacted overall financial results.
Read more →EVOEvotec SE to Announce First Quarter 2026 Results on May 6, 2026
Evotec SE will announce its first quarter 2026 financial results on May 6, 2026. The announcement will be accompanied by a business update during a webcast and conference call. Participants can register for the event to access presentation slides and join the audio call. Evotec continues to emphasize its role in drug discovery and development.
Read more →EVOEvotec Announces New Nomination to Board of Directors
Evotec SE has announced the nomination of Dr. Wolfgang Hofmann as an independent member of its Supervisory Board at the upcoming AGM. This nomination, along with Dieter Weinand's election as Chairman, aims to strengthen governance expertise within the board. Additionally, Evotec has entered a cooperation agreement with key shareholder MAK Capital, emphasizing their commitment to constructive engagement and long-term corporate success. The announcements align with Evotec's strategy to enhance shareholder value through strengthened oversight.
Read more →EVOEvotec Announces Chief Financial Officer Transition Paul Hitchin to step down as of April 30, 2026
Evotec SE has announced a transition in its financial leadership with Chief Financial Officer Paul Hitchin set to step down on April 30, 2026, for personal reasons. He will be succeeded by Claire Hinshelwood, who has extensive experience in financial roles, including positions at BMI Group and Novartis. The company acknowledges Hitchin's substantial contributions during his tenure and expresses confidence in Hinshelwood's ability to guide Evotec towards a new phase of growth and profitability. This leadership change is positioned as a continuation of Evotec's efforts to transform its operations and financial performance.
Read more →About Evotec SE
BIOPHARMAWATCH ELITE PLUS
Trade the next EVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime